$14.00
-0.08 (-0.57%)
Open$14.10
Previous Close$14.08
Day High$14.18
Day Low$13.70
52W High$100.10
52W Low$6.57
Volume—
Avg Volume212.5K
Market Cap669.36M
P/E Ratio—
EPS$-11.45
SectorBiotechnology
Analyst Ratings
Strong Buy
14 analysts
Price Target
+161.9% upside
Current
$14.00
$14.00
Target
$36.67
$36.67
$19.65
$36.67 avg
$47.67
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 85.08M | 76.59M | 82.32M |
| Net Income | 21.83M | 19.00M | 17.76M |
| Profit Margin | 25.7% | 24.8% | 21.6% |
| EBITDA | 33.39M | 28.41M | 32.89M |
| Free Cash Flow | 16.91M | 11.51M | 18.65M |
| Rev Growth | +15.3% | +2.7% | +8.4% |
| Debt/Equity | 0.18 | 0.16 | 0.15 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $207.18 | +0.96% | 166.6 | 397.77B |
| AMGN | Amgen Inc | $353.93 | +1.58% | 24.4 | 188.06B |
| GILD | Gilead Sciences Inc | $138.26 | +0.11% | 20.0 | 170.34B |
| VRTX | Vertex Pharmaceuticals Inc | $454.97 | +1.42% | 29.2 | 115.53B |
| REGN | Regeneron Pharmaceuticals | $749.47 | +1.05% | 17.9 | 80.50B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.70 | +6.70% | 139.7 | 43.84B |